Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The suppression of star formation by powerful active galactic nuclei.
Page MJ, Symeonidis M, Vieira JD, Altieri B, Amblard A, Arumugam V, Aussel H, Babbedge T, Blain A, Bock J, Boselli A, Buat V, Castro-Rodríguez N, Cava A, Chanial P, Clements DL, Conley A, Conversi L, Cooray A, Dowell CD, Dubois EN, Dunlop JS, Dwek E, Dye S, Eales S, Elbaz D, Farrah D, Fox M, Franceschini A, Gear W, Glenn J, Griffin M, Halpern M, Hatziminaoglou E, Ibar E, Isaak K, Ivison RJ, Lagache G, Levenson L, Lu N, Madden S, Maffei B, Mainetti G, Marchetti L, Nguyen HT, O'Halloran B, Oliver SJ, Omont A, Panuzzo P, Papageorgiou A, Pearson CP, Pérez-Fournon I, Pohlen M, Rawlings JI, Rigopoulou D, Riguccini L, Rizzo D, Rodighiero G, Roseboom IG, Rowan-Robinson M, Sánchez Portal M, Schulz B, Scott D, Seymour N, Shupe DL, Smith AJ, Stevens JA, Trichas M, Tugwell KE, Vaccari M, Valtchanov I, Viero M, Vigroux L, Wang L, Ward R, Wright G, Xu CK, Zemcov M. Page MJ, et al. Among authors: levenson l. Nature. 2012 May 9;485(7397):213-6. doi: 10.1038/nature11096. Nature. 2012. PMID: 22575961 Free article.
Submillimetre galaxies reside in dark matter haloes with masses greater than 3 × 10(11) solar masses.
Amblard A, Cooray A, Serra P, Altieri B, Arumugam V, Aussel H, Blain A, Bock J, Boselli A, Buat V, Castro-Rodríguez N, Cava A, Chanial P, Chapin E, Clements DL, Conley A, Conversi L, Dowell CD, Dwek E, Eales S, Elbaz D, Farrah D, Franceschini A, Gear W, Glenn J, Griffin M, Halpern M, Hatziminaoglou E, Ibar E, Isaak K, Ivison RJ, Khostovan AA, Lagache G, Levenson L, Lu N, Madden S, Maffei B, Mainetti G, Marchetti L, Marsden G, Mitchell-Wynne K, Nguyen HT, O'Halloran B, Oliver SJ, Omont A, Page MJ, Panuzzo P, Papageorgiou A, Pearson CP, Pérez-Fournon I, Pohlen M, Rangwala N, Roseboom IG, Rowan-Robinson M, Portal MS, Schulz B, Scott D, Seymour N, Shupe DL, Smith AJ, Stevens JA, Symeonidis M, Trichas M, Tugwell K, Vaccari M, Valiante E, Valtchanov I, Vieira JD, Vigroux L, Wang L, Ward R, Wright G, Xu CK, Zemcov M. Amblard A, et al. Among authors: levenson l. Nature. 2011 Feb 24;470(7335):510-2. doi: 10.1038/nature09771. Epub 2011 Feb 16. Nature. 2011. PMID: 21326201
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Schwartz GG, et al. N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5. N Engl J Med. 2012. PMID: 23126252 Free article. Clinical Trial.
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Schwartz GG, et al. Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017. Am Heart J. 2009. PMID: 19958854 Clinical Trial.
21 results